Need Assistance?

US & Canada:
+
UK: +

FAQs

Resources

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Application Area

Nα-Z-L-lysine amide hydrochloride

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category

CBZ-Amino Acids

Catalog number

BAT-003229

CAS number

112785-42-9

Molecular Formula

C14H21N3O3·HCl

Molecular Weight

315.80

Specification
Reference Reading

IUPAC Name

benzyl N-[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamate;hydrochloride

Synonyms

Z-L-Lys-NH2 HCl; benzyl N-[(2S)-1,6-diamino-1-oxohexan-2-yl]carbamate;hydrochloride

Appearance

White powder

Purity

≥ 98% (HPLC)

Melting Point

155-159 °C

Storage

Store at 2-8 °C

InChI

InChI=1S/C14H21N3O3.ClH/c15-9-5-4-8-12(13(16)18)17-14(19)20-10-11-6-2-1-3-7-11;/h1-3,6-7,12H,4-5,8-10,15H2,(H2,16,18)(H,17,19);1H/t12-;/m0./s1

InChI Key

MDEZKXTTYPBMFC-YDALLXLXSA-N

Canonical SMILES

C1=CC=C(C=C1)COC(=O)NC(CCCCN)C(=O)N.Cl

1.An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.

Johnson FK1, Mudd PN Jr2, DiMino T2, Vosk J1, Sitaraman S1, Boudes P1, France N2, Barlow C1. Clin Pharmacol Drug Dev. 2015 Jul;4(4):256-261. doi: 10.1002/cpdd.149. Epub 2014 Dec 22.

OBJECTIVES: Renal function may progressively decline in patients with Fabry disease. This study assessed pharmacokinetics, safety, and tolerability of a single oral dose of migalastat HCl 150 mg in subjects with normal or mildly, moderately, or severely impaired renal function.